Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,074.68 -5.07 (-0.47%)
Official Closing Price Updated: 7:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
How Abivax Went From Biotech Nobody To M&A Bullseye After A Single Blockbuster Readout This Year ↗
A 1,900% rally, Phase 3 wins, and takeover chatter around Eli Lilly have transformed Abivax from a risky clinical bet into a strategic asset with real optionality. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Head Into Christmas Eve With Caution: Why ASTS, DVAX, ABVX, PATH, GOOGL Are On Traders' Radar Today ↗
Markets are moving from a record-setting close into a thin, holiday-shortened Christmas Eve session. 
Via Stocktwits
Topics ETFs Stocks
News headline image
Novo Nordisk Stock Soars as "Wegovy Pill" Gains FDA Approval, Reshaping Obesity Market
Shares of Novo Nordisk (NYSE: NVO) surged more than 8% in early trading on December 23, 2025, after the pharmaceutical giant secured a landmark FDA approval for its high-dose oral semaglutide, branded... 
Via MarketMinute
Novo Nordisk’s Worst Year In Over Four Decades May Be Ending — Thanks To A Weight-Loss Pill ↗
Via Stocktwits
News headline image
Resilient Prosperity: Blowout Q3 GDP Growth Ignites Year-End Market Surge Amid 'No-Landing' Fears
The United States economy defied gravity in the third quarter of 2025, posting a staggering 4.3% annualized growth rate that has sent shockwaves through global financial markets. Released on December... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
Stock Market Today, Dec. 23: Novo Nordisk Surges After FDA Approves Oral Wegovy Weight Loss Pill ↗
On Dec. 23, 2025, investors weighed a newly approved oral obesity pill’s first-mover edge and its ripple effects across healthcare. 
Via The Motley Fool
Topics Stocks
Fitch Sees Stable 2026 Outlook For Global Pharma — But Warns Trump Drug Pricing Push Poses Profit Risk ↗
Via Stocktwits
Topics Government
News headline image
The Next Big Buyout? Abivax Emerges as a Premier M&A Contender for 2026 Amidst Biotech Consolidation Wave
As the biotech sector closes out a transformative 2025, one name has risen to the top of every institutional investor's watchlist: Abivax (NASDAQ: ABVX). Following a year of stellar clinical results... 
Via MarketMinute
Topics Intellectual Property
News headline image
Novo Nordisk Breaks the Mold: Oral Obesity Breakthrough Sends Shares to New Heights as Pharma Landscape Shifts
BAGSVAERD, Denmark — In a landmark decision that has sent shockwaves through the global pharmaceutical industry, Novo Nordisk (NYSE:NVO) has secured U.S. Food and Drug Administration (FDA) approval for... 
Via MarketMinute
Topics Economy
News headline image
Novo Nordisk&#39;s Wegovy Pill Shakes Up Rivalry With Eli Lilly, Puts Health Care ETFs In Focus ↗
Novo Nordisk's FDA-approved weight-loss pill intensifies its rivalry with Eli Lilly, putting health care and biotech ETFs in focus. 
Via Benzinga
Topics ETFs
News headline image
What&#39;s Going On With Eli Lilly Stock Today? ↗
Eli Lilly And Co (NASDAQ: LLY) shares are trading down on Tuesday as investors weigh the competitive landscape in the pharmaceutical sector. 
Via Benzinga
News headline image
Thin Trading and High Hopes: Markets Eye a 'Santa Claus Rally' as 2025 Draws to a Close
As the sun sets on a volatile but ultimately record-breaking year, Wall Street has entered its final, holiday-shortened trading week of 2025. With the S&P 500 sitting at a historic peak of 6,904 as of... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
Santa Claus Rally Solidifies as S&P 500 Secures Third Consecutive Winning Session Amid Economic Resilience
The U.S. equity markets continued their year-end ascent on Tuesday, December 23, 2025, as the S&P 500 (INDEXSP:.INX) notched its third consecutive winning session. This momentum, often referred to as... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
The Great Biotech Rebound: How Pricing Clarity Rescued the Drug Sector in 2025
After a tumultuous first half of 2025 that saw the pharmaceutical and biotechnology sectors languish under a cloud of regulatory dread, the industry is ending the year on a surprisingly high note. The... 
Via MarketMinute
Topics Economy
News headline image
Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma&#39;s 2026 Comeback ↗
When Mega-cap tech fades, pharma takes spotlight: LLY and NVO are top picks for long-term growth with strong demand for GLP-1 treatments. 
Via Benzinga
Nasdaq, S&P 500 Futures Tread Caution Ahead Of GDP, Confidence Data: Why NVO, ZIM, SIDU Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
3 Reasons Investors Love Eli Lilly (LLY)
Eli Lilly currently trades at $1,061 and has been a dream stock for shareholders. It’s returned 541% since December 2020, blowing past the S&P 500’s 85.2% gain. The company has also beaten the index... 
Via StockStory
Topics Stocks
News headline image
Why Abivax Stock Was on Fire Today ↗
Investors were excited about the possibility of a buyout with a high price tag. 
Via The Motley Fool
News headline image
Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug ↗
The FDA approved a Wegovy pill as the first oral GLP-1 treatment for weight loss. 
Via Investor's Business Daily
News headline image
Novo Nordisk Stock Soars After Hours As FDA Greenlights Wegovy Pill For Weight Loss ↗
The Danish drugmaker expects to launch the pill in the U.S. in January. 
Via Stocktwits
News headline image
The Incretin Empire: Eli Lilly’s (LLY) Path to a $1 Trillion Market Cap and Beyond
As of December 22, 2025, the global equity markets are witnessing a historic recalibration of the healthcare sector. For decades, the "Trillion Dollar Club" was an exclusive enclave for Silicon... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare... 
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Eli Lilly - Momentum Near 52‑Week High As Trade Engine Flags Moderate Strength ↗
Eli Lilly's stock is nearing its 52-week high due to strong momentum and positive news, but upcoming earnings and regulatory developments are crucial for sustaining this performance. 
Via Talk Markets
News headline image
Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? ↗
Novo Nordisk gained a head start in the GLP-1 race but then fell behind; Pfizer is working hard to catch up to the new leader. 
Via The Motley Fool
News headline image
2 Profitable Stocks with Exciting Potential and 1 Facing Challenges
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
ELI LILLY & CO (NYSE:LLY) Combines Strong Earnings Momentum with Bullish Technical Setup ↗
Eli Lilly (LLY) combines explosive earnings growth with a strong technical uptrend, offering a high-momentum investment opportunity within a supportive chart setup. 
Via Chartmill
News headline image
Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump ↗
Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday. 
Via Investor's Business Daily
Topics Government Stocks
News headline image
The Great Biotech Re-Shoring: Seres Therapeutics and the New Commodity-Driven Era
As the final weeks of 2025 unfold, the biotechnology sector is undergoing a fundamental transformation, shifting from a pure-play innovation market to one increasingly dictated by the "physical"... 
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees &#39;Room For Stock Upside&#39; With $3 Billion In Sales By 2026 ↗
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug. 
Via Benzinga
News headline image
1 No-Brainer Growth S&P Index Fund to Buy Right Now for Less Than $500 ↗
This is a quick and easy way to invest in growth. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.